Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Intra-Cellular Therapies Inc. - Common Stock (NQ:ITCI)

131.87 UNCHANGED

Last Price Updated: 4:00 PM EDT, Apr 1, 2025 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	0
Open	131.87
Bid (Size)	131.90 (49)
Ask (Size)	131.92 (100)
Prev. Close	131.87
Today's Range	131.87 - 131.87
52wk Range	126.88 - 131.95
Shares Outstanding	94,324,313
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Johnson & Johnson 2026 Outlook: Chasing the $100 Billion Milestone Amidst Legal and Patent Hurdles

Today 14:23 EST

Following a resilient performance throughout 2025, healthcare giant Johnson & Johnson (NYSE: JNJ) has officially set its sights on a historic milestone for 2026. In its latest earnings report released...

Via MarketMinute

The Biotech Renaissance: Scientific Breakthroughs and M&A Frenzy Spark a New Bull Market

January 22, 2026

The U.S. biotech sector has officially entered a new golden age. As of January 22, 2026, the industry is witnessing a "renaissance" that has effectively erased the memories of the grueling three-year...

Via MarketMinute

Performance

YTD	N/A	N/A
1 Month	N/A	N/A
3 Month	N/A	N/A
6 Month	N/A	N/A
1 Year	+3.7%	+3.7%

More News

Intra-Cellular Therapies Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) ↗

February 21, 2025

Via Benzinga

Demystifying Intra-Cellular Therapies: Insights From 6 Analyst Reviews ↗

January 22, 2025

Via Benzinga

The High-Stakes Balancing Act: Johnson & Johnson Braces for Q4 Earnings Amid Patent Cliffs and MedTech Expansion

January 20, 2026

Via MarketMinute

Biopharma Boom: M&A Frenzy, AI Revolution, and GLP-1 Gold Rush Drive Robust Growth in 2025

November 14, 2025

Via MarketMinute

Why Mark Minervini may look into INTRA-CELLULAR THERAPIES INC (NASDAQ:ITCI) ↗

April 08, 2025

Via Chartmill

Demystifying Intra-Cellular Therapies: Insights From 6 Analyst Reviews ↗

April 02, 2025

Via Benzinga

Stock Of The Day: Will Johnson & Johnson Rally? The Sell-Off May Have Ended ↗

April 02, 2025

Via Benzinga

Evaluating INTRA-CELLULAR THERAPIES INC (NASDAQ:ITCI) using Mark Minervini’s winning stock formula ↗

March 18, 2025

Via Chartmill

Johnson & Johnson Stops Late-Stage Depression Study Over 'Insufficient Efficacy' ↗

March 07, 2025

Via Benzinga

INTRA-CELLULAR THERAPIES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Intra-Cellular Therapies, Inc. - ITCI

February 25, 2025

From Kahn Swick & Foti, LLC

Via Business Wire

ITCI Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Intra-cellular Therapies, Inc. Is Fair to Shareholders

February 24, 2025

From Halper Sadeh LLC

Via Business Wire

Nike To Rally Over 50%? Here Are 10 Top Analyst Forecasts For Monday ↗

February 24, 2025

Via Benzinga

This Conagra Brands Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday ↗

February 24, 2025

Via Benzinga

Axsome's AXS-05 In Alzheimer's Agitation Could Be Billion Dollar Opportunity, Says Analyst ↗

February 18, 2025

Via Benzinga

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LGTY, ENFN, ITCI, SSTK on Behalf of Shareholders

February 04, 2025

From Halper Sadeh LLC

Via GlobeNewswire

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Logility Supply Chain Solutions, Inc. (Nasdaq - LGTY), Enfusion, Inc. (NYSE - ENFN), Intra-Cellular Therapies, Inc. (Nasdaq - ITCI), Shutterstock, Inc. (NYSE - SSTK)

February 04, 2025

From Brodsky & Smith LLC

Via GlobeNewswire

January 27, 2025

From Brodsky & Smith LLC

Via GlobeNewswire

Johnson & Johnson Q4 Earnings: Cancer Drugs Performance Drives Revenue Beat, Issues Strong FY25 Outlook ↗

January 22, 2025

Via Benzinga

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ENFN, ITCI, HEES, SSTK on Behalf of Shareholders

January 21, 2025

From Halper Sadeh LLC

Via GlobeNewswire

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Enfusion, Inc. (NYSE - ENFN), Intra-Cellular Therapies, Inc. (Nasdaq - ITCI), H&E Equipment Services, Inc. (Nasdaq - HEES), Shutterstock, Inc. (NYSE - SSTK)

January 21, 2025

From Brodsky & Smith LLC

Via GlobeNewswire

Top 4 Health Care Stocks You May Want To Dump In Q1 ↗

January 21, 2025

Via Benzinga

MicroStrategy, SoFi Technologies And Carvana Are Among Top Large-Cap Gainers Last Week (Jan 13-Jan 17): Are The Others In Your Portfolio? ↗

January 19, 2025

Via Benzinga

MarketBeat Week in Review – 01/13 - 01/17

January 18, 2025

Via MarketBeat

Frequently Asked Questions

Is Intra-Cellular Therapies Inc. - Common Stock publicly traded?

Yes, Intra-Cellular Therapies Inc. - Common Stock is publicly traded.

What exchange does Intra-Cellular Therapies Inc. - Common Stock trade on?

Intra-Cellular Therapies Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Intra-Cellular Therapies Inc. - Common Stock?

The ticker symbol for Intra-Cellular Therapies Inc. - Common Stock is ITCI on the Nasdaq Stock Market

What is the current price of Intra-Cellular Therapies Inc. - Common Stock?

The current price of Intra-Cellular Therapies Inc. - Common Stock is 131.87

When was Intra-Cellular Therapies Inc. - Common Stock last traded?

The last trade of Intra-Cellular Therapies Inc. - Common Stock was at 04/01/25 04:00 PM ET

What is the market capitalization of Intra-Cellular Therapies Inc. - Common Stock?

The market capitalization of Intra-Cellular Therapies Inc. - Common Stock is 12.44B

How many shares of Intra-Cellular Therapies Inc. - Common Stock are outstanding?

Intra-Cellular Therapies Inc. - Common Stock has 12B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.